Aptose Biosciences (APS) AI Stock Analysis

• Market Cap: C$5.87M
• Dividend Yield: N/A
• Average Volume (3M): 4.26K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.44
• Revenue Growth: N/A
• EPS Growth: 60.95%
• Country: CA
• Employees: 35
• Sector: Healthcare
• Sector Strength: 62
• Industry: Biotechnology
• EPS (TTM): -63.90
• Shares Outstanding: 2,552,429
• 10 Day Avg. Volume: 5,530
• 30 Day Avg. Volume: 4,260
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$13.18
• Price Target Upside: 473.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Aptose Biosciences is in a precarious financial position, typical for biotech companies in the development phase. The stock's technical indicators suggest a bearish trend, and the valuation reflects high uncertainty. However, positive corporate events, including strategic advancements and financial measures, offer some hope for future growth.

Positive Factors

Clinical Development

Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Clinical Trial Results

TUSCANY exhibits initial signs of promise in newly diagnosed AML, with initial safety and efficacy data showing favorable outcomes.

Financial Position

The company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Negative Factors

Funding Needs

Aptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement designed to provide necessary additional funding and accelerate clinical development.

Aptose Biosciences Business Overview & Revenue Model

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

How the Company Makes Money

Aptose Biosciences makes money through the development and potential commercialization of its proprietary pipeline of small molecule therapeutics aimed at treating cancer. Revenue is primarily generated through partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These agreements often include upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on future sales of any successfully developed products. Additionally, Aptose may receive funding from government grants or research institutions to support its drug development efforts. The company's financial success heavily relies on the successful advancement of its drug candidates through clinical trials and obtaining regulatory approvals.

Aptose Biosciences Financial Statement Overview

Summary

Aptose Biosciences exhibits financial instability typical for early-stage biotech firms, with no revenue generation, negative equity, and reliance on external financing. The ongoing operational challenges and lack of revenue present significant risks.

Income Statement

Aptose Biosciences has not generated any revenue over the analyzed periods, resulting in consistently negative profits. The net profit margin, EBIT, and EBITDA margins are all significantly negative, reflecting ongoing operational challenges and lack of revenue generation typical in early-stage biotech companies focused on development.

Balance Sheet

The company's balance sheet shows high leverage with negative stockholders' equity in the latest TTM, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity. This poses significant risk, although earlier periods showed stronger equity positions.

Cash Flow

Cash flow analysis reveals consistently negative operating and free cash flows, with a significant discrepancy between operating cash flow and net income. The company relies heavily on financing activities to sustain operations, which is a typical but risky strategy in pre-revenue biotech companies.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-36.20M	-52.36M	-42.59M	-65.45M	-55.78M	-26.86M
	EBITDA
-35.78M	-52.27M	-42.06M	-64.82M	-55.16M	-26.25M
	Net Income Common Stockholders
-35.80M	-51.21M	-41.05M	-65.26M	-54.71M	-25.70M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.08M	9.25M	46.96M	79.13M	122.39M	97.60M
	Total Assets
2.46M	12.99M	51.03M	82.53M	126.26M	100.48M
	Total Debt
0.00	1.01M	1.30M	574.00K	1.07M	1.53M
	Net Debt
-844.83K	-8.24M	-35.67M	-38.54M	-116.32M	-78.31M
	Total Liabilities
1.36M	15.89M	13.29M	8.29M	7.35M	6.55M
	Stockholders Equity
1.10M	-2.90M	37.74M	74.24M	118.92M	93.93M
Cash Flow		Free Cash Flow
-37.18M	-44.62M	-32.35M	-43.52M	-33.97M	-21.66M
	Operating Cash Flow
-37.18M	-44.59M	-32.32M	-43.30M	-33.89M	-21.56M
	Investing Cash Flow
1.96M	9.96M	30.07M	-35.21M	12.63M	-17.37M
	Financing Cash Flow
27.46M	6.91M	116.00K	226.00K	58.81M	103.45M

Aptose Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APS, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 4.86, below the 50-day MA of 6.34, and below the 200-day MA of 14.55, indicating a bearish trend. The MACD of -0.58 indicates Positive momentum. The RSI at 27.39 is Positive, neither overbought nor oversold. The STOCH value of 10.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APS.

Aptose Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
APS	35 Underperform	C$5.87M	―	391.94%	―	―	60.95%

Aptose Biosciences Corporate Events

Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy

Aptose Biosciences announced the dosing of the first patients in the TUSCANY Phase 1/2 trial, which explores tuspetinib in combination with venetoclax and azacitidine as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This triplet therapy aims to address diverse AML populations and improve response rates and survival while minimizing toxicities, potentially expanding its application to a broader range of AML patients.

Aptose and NCI Collaborate on Cancer Drug Trials

Aptose Biosciences has partnered with the National Cancer Institute to develop tuspetinib for acute myeloid leukemia and myelodysplastic syndromes as part of the myeloMATCH precision medicine trials. The collaboration aims to enhance treatment options for these blood cancers through targeted drug combinations, offering new hope for patients. This initiative highlights tuspetinib’s potential in treating challenging genetic cases of AML and MDS.

Aptose Biosciences Launches TUSCANY Study for AML

Aptose Biosciences has launched the TUSCANY Phase 1/2 study to test a new triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This innovative treatment combines tuspetinib with azacitidine and venetoclax, aiming to offer an effective frontline therapy for AML patients who cannot undergo intensive chemotherapy. The trial is being conducted across several sites in the United States, with potential to impact a broad range of AML cases.

Aptose Biosciences Advances AML Triplet Therapy

Aptose Biosciences is advancing the development of its promising drug tuspetinib as part of a triplet therapy for acute myeloid leukemia (AML), showing strong clinical activity and a unique safety profile. The company has secured a $10 million loan from Hanmi Pharmaceutical to support the clinical development of tuspetinib, with plans for a new co-development collaboration. Tuspetinib has demonstrated potential to address unmet needs in AML treatment by avoiding common toxicities associated with other therapies.